Explore GEN family of websites, social media experiences, blogs and more.

Unleashing ideas.
Strengthening startups.

Back to search results
    Date submitted
  • 22-Dec-2015

PathoVax

Abstract

RGVax is a universal HPV vaccine that addresses the devastating economic burden, social stigma, costly manufacturing, and poor compliance rates resulting from the incomplete protection of current vaccines. The RGVax prototype utilizes similar technology as approved vaccines to conserve safety profiles, yet provides protection against at least 27 HPVs, including all 15 high-risk cervical cancer causing types, with one VLP. RGVax is the first solution to eradicate HPV.

Video

Additional Questions

Investor questions have not yet been answered for this business